Skip to main content
Premium Trial:

Request an Annual Quote

And We Thought They Were Joined at the Hip

23andMe's Linda Avey is leaving the personal genomics company to start a nonprofit foundation, reports TechCrunch. According to an email Avey sent to employees, her new foundation will focus on Alzheimer's disease research and "will leverage the research platform we've built at 23andMe — the goal is to drive the formation of the world's largest community of individuals with a family history of Alzheimer's, empower them with their genetic information and track their brain health using state-of-the-art tools," the email says. Avey adds that this decision was in part based on her father-in-law suffering from Alzheimer's disease. Avey co-founded 23andMe with Anne Wojcicki in 2006.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.